Using precision medicine
to improve patient outcomes
PrismRA® introduces precision medicine to the treatment of rheumatoid arthritis for the first time, providing objective, science-based guidance for rheumatoid arthritis (RA) therapy selection. The test leverages RNA sequencing (RNAseq) and gene expression data to identify patients who are unlikely to adequately respond to TNF inhibitor (TNFi) therapies, a targeted therapy commonly used to treat RA, based on their distinct molecular signatures.
The PrismRA test analyzes 23 biological features, including single-nucleotide polymorphisms (SNPs) derived from RNAseq, gene expression levels, serum peptides and disease-associated clinical features, that are discriminatory between the molecular signatures of those who respond or do not respond adequately to TNFi therapies.
Identifying molecular signatures indicative of inadequate response
Like fingerprints, molecular signatures are unique. They reveal how diseases affect each patient differently. A molecular signature combines a set of biological features to capture an individual’s genetic makeup and disease behavior. These features include RNA, proteins, and other features that reflect a patient’s distinctive disease biology.
Targeted therapies, like TNFi therapies, target specific disease related proteins. Because a disease affects each patient differently, a targeted therapy may work for some patients but not others. An RA patient may fail to have an adequate response to a TNFi therapy if his or her molecular signature is not sufficiently driven by the
PrismRA combines RNAseq and gene expression data to increase a molecular signature’s power to predict if a patient will respond inadequately to a TNFi therapy.